FDA Approves Expanded Label for Merck ’s Keytruda (pembrolizumab) in Patients with Metastatic Nonsquamous NSCLC with No EGFR or ALK Genomic Tumor Aberrations

KENILWORTH, N.J.--(BUSINESS WIRE) August 20, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck ’s...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news